Acumen Pharmaceuticals (ABOS) Debt Ratio (2025 - 2026)
Acumen Pharmaceuticals recorded quarterly Debt Ratio of 0.11 in Q1 2026, up 48.11% quarter-over-quarter from 0.07 in Q4 2025.
Acumen Pharmaceuticals' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.11 for Q1 2026.
- In Q1 2026, Debt Ratio changed N/A year-over-year to 0.11; the TTM figure through Mar 2026 stood at 0.11 (changed N/A YoY), while the FY2025 annual figure was 0.07, changed N/A from the prior year.
- Debt Ratio came in at 0.11 for Q1 2026 at Acumen Pharmaceuticals, up from 0.07 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.11 in Q1 2026 to a low of 0.03 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | 0.11 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.11 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | 0.03 |